← Back to headlines
Karyopharm, Cormedix Outline 2026 Revenue Outlooks
Pharmaceutical companies Karyopharm and Cormedix have provided their respective revenue outlooks for 2026. Karyopharm anticipates $130M-$150M, while Cormedix projects $325M-$345M amid a TDAPA transition.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
